Showing results (1691-1700 of 1,814) with videos related to

Sort By:
Pageof 182
The Lancet. Respiratory Medicine|July 9, 2019
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trialSteven Pascoe, Neil Barnes, Guy Brusselle, et al.
European Urology|July 8, 2015
Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic ProfilingSumanta K Pal, Toni K Choueiri, Kai Wang, et al.
Nature Communications|October 10, 2020
Identification of 31 loci for mammographic density phenotypes and their associations with breast cancer riskWeiva Sieh, Joseph H Rothstein, Robert J Klein, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2015
Cold season emissions dominate the Arctic tundra methane budgetDonatella Zona, Beniamino Gioli, Róisín Commane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047Evan J Lipson, Sonia Dolfi, Hao Tang, et al.
The Oncologist|July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapyMonica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.
The Journal of Pediatrics|March 6, 2009
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled studyFriedrich K Trefz, Barbara K Burton, Nicola Longo, et al.
Human Mutation|January 22, 2008
Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinaseD P Dimmock, Q Zhang, C Dionisi-Vici, et al.
NEJM Evidence|February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced MelanomaGeorgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Journal of the National Cancer Institute|July 21, 2026
Summary recommendations from the NCI clinical trials planning meeting (CTPM) on advanced cutaneous squamous cell carcinoma in immunosuppressed patientsShlomo A Koyfman, Julie E Bauman, Mehrdad Mohseni, et al.
Pageof 182